Cargando…

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants

Detalles Bibliográficos
Autores principales:	Tartof, Sara Y, Slezak, Jeff M, Puzniak, Laura, Hong, Vennis, Xie, Fagen, Ackerson, Bradley K, Valluri, Srinivas R, Jodar, Luis, McLaughlin, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075856/ https://www.ncbi.nlm.nih.gov/pubmed/35533699 http://dx.doi.org/10.1016/S2213-2600(22)00170-9

Ejemplares similares

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years
por: Tartof, Sara Y., et al.
Publicado: (2022)

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
por: Tartof, Sara Y, et al.
Publicado: (2023)

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5–11 Years of Age: A Test Negative Design
por: Tartof, Sara Y, et al.
Publicado: (2023)

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
por: Tartof, Sara Y., et al.
Publicado: (2022)

Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
por: Tartof, Sara Y., et al.
Publicado: (2023)

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
por: Tartof, Sara Y, et al.
Publicado: (2021)

Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
por: Khan, Farid L., et al.
Publicado: (2022)

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
por: Lewnard, Joseph A, et al.
Publicado: (2023)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective
por: Jatoi, Hafsa Nazir, et al.
Publicado: (2022)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System
por: Malden, Deborah E, et al.
Publicado: (2022)

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine
por: McGrath, Leah J., et al.
Publicado: (2023)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023)

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
por: Hansen, Lena, et al.
Publicado: (2023)

2349. Natural Killer Cells and BNT162b2 mRNA Vaccine Reactogenicity and Durability
por: Graydon, Elizabeth K, et al.
Publicado: (2023)

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
por: Canti, Lorenzo, et al.
Publicado: (2022)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12–18 years group
por: Ergoren, Mahmut Cerkez, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
por: Tan, Sharon H.X., et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1gph6d637nikb7tg0h7sv8b9u